Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma

• DOI: 10.1084/jem.20180749
• Publication Date: 2019-02-07T19:46:18Z
• Authors: Jing Liu; Wenna Jiang; Kaili Zhao; Hongwei Wang; Tianxing Zhou; Weiwei Bai; Xiuchao Wang; Tiansuo Zhao; Chongbiao Huang; Song Gao; Tai Qin; Wenwen Yu; Bo Yang; Xin Li; Danqi Fu; Wei Tan; Shengyu Yang; He Ren; Jihui Hao
• Keywords: Immune checkpoint; Myeloid-derived Suppressor Cell

Pancreatic ductal adenocarcinoma (PDAC) is a highly immune-suppressive tumor with low response rate to single checkpoint blockade therapy. ETS homologous factor (EHF) suppressor in PDAC. Here, we report novel function of EHF pancreatic cancer immune microenvironment editing and efficacy prediction for anti-PD1 Our findings support that the deficiency tumoral induced accumulation regulatory T (T reg) cells myeloid-derived (MDSCs) decrease number tumor-infiltrating CD8+ cells. Mechanistically, conversion expansion reg MDSCs through inhibiting TGFβ1 GM-CSF secretion. suppressed transcription TGFB1 CSF2 by directly binding their promoters. Mice bearing overexpression tumors exhibited significantly better therapy than those control tumors. delineate immunosuppressive mechanism PDAC highlight may improve immunotherapy.